Johnson & Johnson gains after slightly beating expectations for 3Q24 📊

3:59 PM 15 October 2024

Johnson & Johnson (JNJ.US) released its 3Q24 results today. The company's sales in MedTech segment turned out to be lower than market forecasts, however, on the profitability level J&J positively surprised the market. The company's stock price is approaching the upper limits of the broad downtrend the company has been in since the beginning of this year. 


Source: xStation

The company reported sales of $22.47 billion, a slight improvement over the previous year (+5.5% y/y). The strongest sales growth was recorded by the Darzalex product, whose revenues increased by 21% y/y. In the MedTech segment, the company reported PLN 7.89 billion, which was weaker than market expectations. 

Adj. EPS fared better, coming in at $2.42, beating expectations of $2.19/share. The adjustment included about $3 billion in one-time event costs related to legal and acquisition costs. 

Johnson & Johnson lowered its profitability projections for the full year 2024, mainly due to the V-Wave acquisition. The company's new projections call for adjusted earnings per share in the range of: $9.88-$9.98 (vs. previous projections of $9.97-$10.07). 

 

3Q24 RESULTS:

  • Sales $22.47 billion, estimates $22.16 billion
    • MedTech revenues $7.89 billion, +5.8% y/y, estimates $8.03 billion
    • Imbruvica revenues $753 million, -6.8% y/y, estimates $746.2 million
    • Darzalex revenues $3.02 billion, +21% y/y, $2.94 billion estimate
    • Erleada revenues $790 million, estimate $766.4 million
    • Tremfya revenues $1.01 billion, +13% y/y, $1.06 billion estimate
    • Remicade revenues $419 million, -9.1% y/y, $324.7 million estimate
    • Stelar revenues $2.68 billion, -6.6% y/y, $2.61 billion estimate
    • Zytiga revenues $150 million, -30% y/y, $144.2 million estimate
    • Xarelto revenues $592 million, -5.3% y/y, $563.5 million estimate
    • Simponi revenues $516 million, -18% y/y, $476.9 million estimate
  • Adjusted EPS $2.42, estimate $2.19
Share:
Back

Join over 1 600 000 XTB Group Clients from around the world

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits